Monitor for future IND-enabling study initiation and larger-scale manufacturing progress. Any upcoming financing will likely be dilutive given small market cap ($7M). Watch for replication of results in GLP or large-animal studies.
Price Chart
Executive Summary
Alaunos Therapeutics released early non-GLP preclinical data from two diet-induced obesity (DIO) mouse studies showing that its lead drug candidate, ALN1003, produced dose-dependent body weight loss, favorable body composition changes, reduced liver weight, and improved metabolic biomarkers. While the results are encouraging for a non-hormonal obesity treatment, the data are preliminary and subject to limitations, including potential confounding from reduced food and water intake in treated mice.
Key Facts
- ALN1003 showed up to -12.9% mean body weight change vs control (p<0.0001) in DIO mice after 34 days
- Liver weight reduced by up to 55% (high dose group, p<0.01) and liver enzymes (ALT, AST, ALP) improved
- High-dose group had 197 mg/dL glucose vs 320 mg/dL in controls (p<0.0001), and lower total cholesterol
- Drug was generally well tolerated, though mild hypolocomotion and dehydration in high-dose mice were observed
- Company has $1.9M cash as of Sept 30, 2025, with runway into Q2 2026; additional financing planned
Financial Impact
No immediate financial impact; preclinical stage with no revenue or earnings. Cash runway extends to Q2 2026 with $1.9M, but dilutive financing likely needed.
Risk Factors
- Preclinical mouse data may not translate to humans
- Behavioral avoidance of medicated water may confound efficacy interpretation
- Cash runway ends in Q2 2026; high risk of dilutive financing
- Early-stage biotech with no clinical data or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247189 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 29, 2026 13w ago | 8-K | $2.37 $1.27 | ▼ −46.41% | ▼ −50.80% | $0.9100 (−61.60%) |
May 26, 2026 18w ago | 8-K | $2.45 $1.88 | ▲ +23.27% | ▲ +25.99% | $0.9100 (+62.86%) |
Apr 15, 2026 24w ago | 8-K | $2.83 $2.08 | ▲ +26.36% | ▲ +33.41% | $0.9100 (+67.84%) |
Mar 2, 2026 30w ago | Press Release | $3.32 $2.45 | ▼ −26.20% | ▼ −35.53% | $0.9100 (−72.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access